TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00721448
Drug: AZD6140
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 x 2 mg tablets, oral, once daily for the first day and twice daily from day 4 to 9
Study: NCT02925000
Drug: TLC178
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC178
Study: NCT00736450
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00736450
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00680342
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700mg dose (5 pills, three times daily) for 24-week treatment period
Study: NCT00680342
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 420mg dose (5 pills, three times daily) for 24-week treatment period
Study: NCT00078572
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.
Study: NCT00790192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo to Lurasidone or Quetiapine
Study: NCT04282668
Drug: TAS1440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: Capsule or Tablet Route of Administration: Oral
Study: NCT00332644
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage same as active drug conditions
Study: NCT00255281
Drug: AZD7009, no generic name available
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02104648
Drug: RO4602522
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, oral dose
Study: NCT02935530
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4250KU, subcutaneous injection of 5-10 days
Study: NCT00250237
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1mg twice daily during 72hours
Study: NCT01616654
Drug: CD5789 25 µg/g cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD5789 25 µg/g cream applied once daily
Study: NCT01616654
Drug: CD5789 50 µg/g cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD5789 50 µg/g cream applied once daily
Study: NCT01616654
Drug: CD5789 100 µg/g cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD5789 100 µg/g cream applied once daily
Study: NCT01616654
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied once daily
Study: NCT02817217
Drug: SP2086
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
Study: NCT00606580
Drug: WR 279,396 topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
Study: NCT00606580
Drug: Paromomycin Alone topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
Study: NCT00606580
Drug: Vehicle placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
Study: NCT02169154
Drug: 1% Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% diclofenac sodium
Study: NCT02493036
Drug: SYN-010
Normalized name: Gel-Syn
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01645254
Drug: Argemone mexicana
Normalized name: ARGEMONE MEXICANA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30g, the powder decoction 2 times a day for 14 days
Study: NCT02169154
Drug: 0.9% Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Saline
Study: NCT03456817
Drug: Control Arm - standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The historical controls will have received and the concurrent controls will receive our standard GVHD prophylaxis, ie, ATG 4.5 mg/kg i.v. (0.5 mg/kg on day -2, 2.0 mg/kg on day -1 and 2.0 mg/kg on day 0), MTX (15 mg/m2 i.v. on day 1 and 10 mg/m2 i.v. on days 3, 6 and 11) and CSA (2.5 mg/kg twice a day i.v. starting from day -1, adjusting dose to target trough plasma CSA levels of 200-400 microg/L, switching to oral formulation before discharge from peritransplant hospitalization, targeting the trough plasma levels of 200-400 microg/L until day 56, and tapering to zero between day 56 and 84).
Study: NCT03983889
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
Study: NCT03983889
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
Study: NCT00923676
Drug: fenofibrate + rosuvastatin
Normalized name: rosuvastatin and fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
Study: NCT02303444
Drug: Other Multikinase inhibitors
Normalized name: ACE inhibitors, other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients can get MKIs at any time during study.
Study: NCT05719818
Drug: biphosphonates
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of bisphosphonate therapy
Study: NCT01468740
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain doxorubicin.~* Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.
Study: NCT00159354
Drug: predisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05329454
Drug: Ibuprofen Tablets
Normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment A:~One tablet of IBUMR will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBUMR every 12 hours for a total of 7 doses.~Treatment B:~One tablet of IBURed will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBURed every 8 hours for a total of 10 doses.~Treatment C:~Single dose of IBUMR will be given to the subjects under fed condition (a standard high-fat, high calorie breakfast should be consumed within 30 minutes prior to dosing).
Study: NCT03646006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL normal saline
Study: NCT02734628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Bepanthen® ointment without active ingredient dexpanthenol
Study: NCT01468740
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The seven-drug BEACOPP-baseline chemotherapy regimen contains cyclophosphamide.~* Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~* Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation.
Study: NCT03608618
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous administration for preconditioning
Study: NCT00612586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, daily (up to 1 yr or until progressive disease)
Study: NCT00612586
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 milligram per meter squared (mg/m\^2) intravenously (IV), Day 1 of 14 day cycle (up to 1 yr or until progressive disease)
Study: NCT00542087
Drug: MK0663, etoricoxib / Duration of Treatment: 6 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00542087
Drug: Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00750750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
Study: NCT00624312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days prior to surgery - injection with 60,000 IU of placebo~Day of surgery - injection with 60,000 IU of placebo
Study: NCT00988078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule (without biologic action) administered three times a day for six months
Study: NCT00949975
Drug: AZD9668
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 30 mg oral tablets twice daily (bid) for 12 weeks
Study: NCT00949975
Drug: AZD9668
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 10 mg oral tablets twice daily (bid) for 12 weeks
Study: NCT00949975
Drug: AZD9668
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
Study: NCT00949975
Drug: AZD9668 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
Study: NCT00922207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: From week -4 to week 2
Study: NCT02311907
Drug: Glutathione
Normalized name: Glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV, over 15 minutes, immediately before chemotherapy administration
Study: NCT03969472
Drug: probiotics
Normalized name: probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: apply probiotic after operation
Study: NCT00491517
Drug: conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs for patients with high blood pressure.
Study: NCT01677325
Drug: Chinese herb (YiQiSanJu)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herb formula:Huangqi,huanglian,yinchen,ect
Study: NCT01553721
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase IIa - placebo Phase IIb - placebo
Study: NCT01312441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by mouth once weekly for 6 months
Study: NCT00166166
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.
Study: NCT03699293
Drug: celecoxib 200mg capsule
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib 200mg twice a day for 4 weeks
Study: NCT03699293
Drug: naproxen sodium 550mg tablet
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen sodium 550mg twice a day for 4 weeks
Study: NCT00988637
Drug: Vectical™ Ointment weekdays and Clobex® Spray weekends regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
Study: NCT00988637
Drug: Clobex® Spray morning and Vectical™ Ointment evening regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
Study: NCT04677322
Drug: Adult patients diagnosed and treated for high blood pressure
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program interventions conducted by primary care staff to encourage adherence to a low-sodium diet consisting of direct action on the patient and provision of educational materials will be assessed. Compliance and follow-up of the low sodium diet will be done by monitoring the sodium in urine in the target population, selected according to the selection criteria described in the protocol.
Study: NCT02052375
Drug: ASP2408
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT02052375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT02794766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 gum each 12 hours for 10 days
Study: NCT04191486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT00647530
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00647530
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03035045
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03762031
Drug: GC4711 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose given via a 15 minute intravenous infusion
Study: NCT03762031
Drug: GC4711 60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose given via a 15 minute intravenous infusion
Study: NCT03762031
Drug: GC4711 90mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose given via a 15 minute intravenous infusion
Study: NCT03762031
Drug: GC4711 120mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose given via a 15 minute intravenous infusion
Study: NCT03762031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of normal saline given via a 15 minute intravenous infusion
Study: NCT03762031
Drug: GC4711 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose given via a 15 minute intravenous infusion
Study: NCT03762031
Drug: GC4711 105mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose given via a 15 minute intravenous infusion
Study: NCT04626375
Drug: Bioarginine
Normalized name: Tilarginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the Bioarginine group the partecipants take bioarginine (2 vials per os of 1.66 g every 12 hours) for 4 week
Study: NCT04626375
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the Placebo group the participants take bio-arginine (2 vials per os of 1.66 g every 12 hours) for 4 week
Study: NCT02884544
Drug: HLD100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment
Study: NCT02008084
Drug: TRIA-662
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
Study: NCT02008084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
Study: NCT04102371
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride.
Study: NCT04102371
Drug: Plasma-lyte
Normalized name: Plasma-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: PL is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C6H11NaO7); 368 mg of Sodium Acetate Trihydrate, USP (C2H3NaO2•3H2O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl2•6H2O). It contains no antimicrobial agents. The pH is adjusted with sodium hydroxide. The pH is 7.4 (6.5 to 8.0).
Study: NCT00102128
Drug: Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00924534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00924534
Drug: SLV337
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV337 400 mg/day
Study: NCT00924534
Drug: SLV337
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV337 800 mg/day
Study: NCT00924534
Drug: SLV337
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV337 1400 mg/day
Study: NCT02412228
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycle 1:~Cyclophosphamide: 50 mg/day continuous daily~Cycles 2-6:~Cyclophosphamide: 50 mg/day continuous daily
Study: NCT00044213
Drug: EDTA Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 40 infusions of EDTA placebo.
Study: NCT03008915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo taken once per day in the morning
Study: NCT00118404
Drug: Continuation phase fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage of fluoxetine was increased to 40 mg over 8 months.
Study: NCT01585558
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00287716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
Study: NCT02085018
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT00755118
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
Study: NCT02766868
Drug: FACE-Flu/Bu/Cy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
Study: NCT00393211
Drug: MK0663, Etoricoxib / Duration of Treatment : 12 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00393211
Drug: Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01705249
Drug: 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
Study: NCT01922271
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)
Study: NCT01922271
Drug: Placebo to NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).
Study: NCT00457691
Drug: 5 fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
Study: NCT00457691
Drug: levo- leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg/m2 iv; day 1 every 14 days
Study: NCT00457691
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
Study: NCT01720563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
Study: NCT00346125
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 65 mg/m\^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1
Study: NCT00346125
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
Study: NCT01101685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days dosing at 10mg daily
Study: NCT06188611
Drug: Huazhi Rougan Granule Placebo granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: Huazhi Rougan granule Placebo Comparator: Placebo granule Placebo Comparator: Placebo granule
Study: NCT04633980
Drug: Mixture 3,6% H2 in N2 (96.4%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration: intra-nasal Debit 1L/min, 24h/24h (3 hours withdrawal tolerated) duration of treatment: 24 hours, 3 days and 6 days
Study: NCT02758912
Drug: оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00328393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01559480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule takes 1 capsule before bedtime for 6 months
Study: NCT00453323
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 900mg/m2 bid po on day 1\~14, 1 weeks rest, until disease progression
Study: NCT02996500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00391547
Drug: Frio Oral Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03828162
Drug: Anticoagulants
Normalized name: ANTICOAGULANTS
Approvals — FDA: no, EMA: no, PMDA: no